Osteonecrosis of the Jaw (ONJ) Case Registry

NCT ID: NCT01666106

Last Updated: 2020-12-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

327 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-10-01

Study Completion Date

2020-12-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Osteonecrosis of the Jaw (ONJ) Case Registry

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of the ONJ case registry is to describe the natural history of positively-adjudicated ONJ in subjects with cancer with an observation period of 5 years. Most of these subjects are expected to have received bone antiresorptive agents such as bisphosphonates or denosumab together with cancer-specific therapies (eg, chemotherapy, steroids, or anti-angiogenics). It is also possible that the registry will include subjects with cancer who developed ONJ without exposure to any antiresorptive therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteonecrosis of the Jaw

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects with cancer and ONJ

Subjects with cancer and positively adjudicated ONJ

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult (≥18 years of age) with diagnosis of cancer
* Newly diagnosed, positively-adjudicated ONJ
* ECOG \<=2 and expected survival ≥3 months
* Willing to provide access to previous and future medical and dental information
* Subject or subject's legally acceptable representative has provided written informed consent

Exclusion Criteria

* History of radiation to the jaws administered for the treatment of cancer
* Subject will not be available for protocol required study visits, to the best of the subject and investigator's knowledge.
* Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amgen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MD

Role: STUDY_DIRECTOR

Amgen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Beverly Hills, California, United States

Site Status

Research Site

Duarte, California, United States

Site Status

Research Site

Denver, Colorado, United States

Site Status

Research Site

Farmington, Connecticut, United States

Site Status

Research Site

Stratford, Connecticut, United States

Site Status

Research Site

Washington D.C., District of Columbia, United States

Site Status

Research Site

Gainesville, Florida, United States

Site Status

Research Site

Atlanta, Georgia, United States

Site Status

Research Site

Chicago, Illinois, United States

Site Status

Research Site

Council Bluffs, Iowa, United States

Site Status

Research Site

Baltimore, Maryland, United States

Site Status

Research Site

Omaha, Nebraska, United States

Site Status

Research Site

Omaha, Nebraska, United States

Site Status

Research Site

Buffalo, New York, United States

Site Status

Research Site

Buffalo, New York, United States

Site Status

Research Site

Mineola, New York, United States

Site Status

Research Site

Charlotte, North Carolina, United States

Site Status

Research Site

Cleveland, Ohio, United States

Site Status

Research Site

Philadelphia, Pennsylvania, United States

Site Status

Research Site

Memphis, Tennessee, United States

Site Status

Research Site

Nashville, Tennessee, United States

Site Status

Research Site

Houston, Texas, United States

Site Status

Research Site

Brussels, , Belgium

Site Status

Research Site

Edegem, , Belgium

Site Status

Research Site

Leuven, , Belgium

Site Status

Research Site

Halifax, Nova Scotia, Canada

Site Status

Research Site

Greater Sudbury, Ontario, Canada

Site Status

Research Site

Kitchener, Ontario, Canada

Site Status

Research Site

Sault Ste. Marie, Ontario, Canada

Site Status

Research Site

Québec, Quebec, Canada

Site Status

Research Site

Aarhus C, , Denmark

Site Status

Research Site

København Ø, , Denmark

Site Status

Research Site

Helsinki, , Finland

Site Status

Research Site

Kuopio, , Finland

Site Status

Research Site

Oulu, , Finland

Site Status

Research Site

Bordeaux, , France

Site Status

Research Site

Brest, , France

Site Status

Research Site

Lyon, , France

Site Status

Research Site

Paris, , France

Site Status

Research Site

Saint-Herblain, , France

Site Status

Research Site

Berlin, , Germany

Site Status

Research Site

Berlin, , Germany

Site Status

Research Site

Cologne, , Germany

Site Status

Research Site

Düsseldorf, , Germany

Site Status

Research Site

Mühlhausen, , Germany

Site Status

Research Site

München, , Germany

Site Status

Research Site

München, , Germany

Site Status

Research Site

Regensburg, , Germany

Site Status

Research Site

Athens, , Greece

Site Status

Research Site

Athens, , Greece

Site Status

Research Site

Thessaloniki, , Greece

Site Status

Research Site

Thessaloniki, , Greece

Site Status

Research Site

Alessandria, , Italy

Site Status

Research Site

Brescia, , Italy

Site Status

Research Site

Lecce, , Italy

Site Status

Research Site

Roma, , Italy

Site Status

Research Site

Torino, , Italy

Site Status

Research Site

Seville, Andalusia, Spain

Site Status

Research Site

Barcelona, Catalonia, Spain

Site Status

Research Site

Madrid, , Spain

Site Status

Research Site

Madrid, , Spain

Site Status

Research Site

Cardiff, , United Kingdom

Site Status

Research Site

London, , United Kingdom

Site Status

Research Site

Sheffield, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Canada Denmark Finland France Germany Greece Italy Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Schiodt M, Vadhan-Raj S, Chambers MS, Nicolatou-Galitis O, Politis C, Coropciuc R, Fedele S, Jandial D, Zhang J, Ma H, Saunders DP. A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer. Support Care Cancer. 2018 Jun;26(6):1905-1915. doi: 10.1007/s00520-017-4003-2. Epub 2017 Dec 23.

Reference Type BACKGROUND
PMID: 29275525 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.amgentrials.com

AmgenTrials clinical trials website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20101102

Identifier Type: -

Identifier Source: org_study_id